SAR 438335Alternative Names: SAR438335
Latest Information Update: 10 Feb 2016
At a glance
- Originator Sanofi
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Diabetes mellitus
Most Recent Events
- 31 Oct 2015 Phase-I clinical trials in Diabetes mellitus in France (unspecified route) before October 2015